CD36 and atherosclerosis: A recent in vivo study demonstrated that deleting Trpm2 or inhibiting TRPM2 activity in cultured macrophages suppressed the CD36 signaling cascade induced by oxidative low-density lipoprotein and TSP1, suggesting that TRPM2 is an effective therapeutic target for atherosclerosis (Fig. 1) [23].